Results 241 to 250 of about 78,313 (276)

Modification of Urokinase

Annals of the New York Academy of Sciences, 1988
Developpement d'un nouveau procede de modification de l'urokinase par la serumalbumine humaine. Avantages de cette urokinase modifiee: resistance a la chaleur, a la pepsine et a un inhibiteur placentaire de l ...
Guodong Mao, Bingzhao Shi, Zhenping Xiong   +2 more
openaire   +3 more sources

Magnetic urokinase: Targeting of urokinase to fibrin clot

Biochemical and Biophysical Research Communications, 1988
A plasminogen activator of human origin, urokinase, was endowed with magnetic property. The magnetic urokinase was composed of magnetite, polyethylene glycol derivative and urokinase, and dispersed in saline. Its particle size of magnetite was approximately 30-60 nm.
Tatsuyuki Yoshimoto, Kimiko Ohwada, Katsunobu Takahashi, Ayako Matsushima, Yuji Saito, Yuji Inada   +5 more
openaire   +3 more sources

6 The urokinase/urokinase-receptor system and cancer invasion

Baillière's Clinical Haematology, 1995
u-PA binds with high affinity to its specific GPI-anchored receptor on the cell surface. The binding has at least two important consequences: (1) it enhances the rate of plasminogen activation on the cell surface; and (2) it focuses the u-PA proteolytic activity at the leading front of migrating cells. Several recent findings suggest that surface-bound
CONESE, MASSIMO, F. Blasi
openaire   +3 more sources

The kringle stabilizes urokinase binding to the urokinase receptor

Blood, 2003
AbstractThe structural basis of the interaction between single-chain urokinase-type plasminogen activator (scuPA) and its receptor (uPAR) is incompletely defined. Several observations indicated the kringle facilitates the binding of uPA to uPAR. A scuPA variant lacking the kringle (ΔK-scuPA) bound to soluble uPAR (suPAR) with the similar “on-rate” but ...
Abd Al-Roof Higazi, Andrew P. Mazar, Khalil Bdeir, Alice Kuo, Douglas B. Cines, Bruce S. Sachais, Ann H. Rux, Yasmina Bdeir   +7 more
openaire   +3 more sources

Effects of Pro-Urokinase and Urokinase on the Fibrinolytic System in Man

Pathophysiology of Haemostasis and Thrombosis, 1987
The fibrinolytic and fibrinogenolytic properties of kidney cell pro-urokinase (PUK) were compared with those of natural urinary urokinase in human volunteers. Comparable degrees of fibrinolysis were obtained at a concentration of 500,000 U UK and a concentration of 500,000 IU natural urokinase.
Dieter Welzel, Gustav Trübestein, Wolf Helmut, Smilja Popov   +3 more
openaire   +2 more sources

Studies on the Biochemistry of Urokinase

Thrombosis and Haemostasis, 1977
SummaryDirect evidence for an active center histidine residue in urokinase (UK) was obtained with use of newly synthesized peptide chloroketones Ac-Gly-Lys-CH2C1 and Nle-Gly-Lys-CH2C1. Stoichiometric inactivation by DFP provided further evidence that UK is a serine protease.
Guenther Schoellmann, Mercedes E. Soberano, Eng Bee Ong, Alan J. Johnson   +3 more
openaire   +3 more sources

The biochemistry and physiology of urokinase

The American Journal of Cardiology, 1960
Abstract Development of methods for isolating, purifying and assaying urokinase, the urinary enzyme activator of plasma profibrinolysin, is described. Properties of the enzyme are given and the unit of activity is defined and related to units of other workers.
David R. Celander, M. Mason Guest
openaire   +3 more sources

Urokinase and Infarction

JAMA: The Journal of the American Medical Association, 1974
To the Editor.— I was interested in the fortunately brief report on the use of urokinase in the treatment of acute myocardial infarction (228:1629, 1974). Although I don't feel inclined to call a press conference, I think it might be in order to set the record straight. I am referring to Dr. M. S.
Richard D. Sautter, William O. Myers, Jefferson F. Ray   +2 more
openaire   +2 more sources

Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase) [PDF]

, 2001
The discovery of urokinase (UK) is described in chap. 4. The UK in urine is not a waste product as shown by studies of the fate of intravenous injections of UK, which was found not to be excreted by the kidney (Fletcher et al. 1965). Instead, it is secreted by renal tubular cells (Sappino et al.
openaire   +1 more source

Urokinase in Pulmonary Embolism

New England Journal of Medicine, 1967
THE use of thrombolytic enzymes or their activators has been proposed as a treatment of thromboembolic diseases such as pulmonary embolism. Using streptokinase as the plasminogen activator, Johnson and McCarty1 demonstrated the efficacy of thrombolytic therapy in the lysis of venous thrombi induced in human volunteers.
Ursula Scheffel, Richard A. Holmes, Donald E. Tow, Henry N. Wagner, Rosemary Longo, James K. Langan, Katharine S. Harrison   +6 more
openaire   +3 more sources